Bie M. P. Verbist

发表

Low-frequency variant detection in viral populations using massively parallel sequencing data

Bie M. P. Verbist, 2014 .

VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering

Jeroen Aerssens, Willem Talloen, Koen Van der Borght, 2015, Bioinform..

QQ-SNV: single nucleotide variant detection at low frequency by comparing the quality quantiles

Jeroen Aerssens, Koen Van der Borght, Herman van Vlijmen, 2015, BMC Bioinformatics.

High-Dimensional Biomarkers in Drug Discovery: The QSTAR Framework

Adetayo Kasim, Ziv Shkedy, Hinrich W. H. Göhlmann, 2016 .

ViVaMBC: estimating viral sequence variation in complex populations from illumina deep-sequencing data using model-based clustering

Luc Bijnens, Jeroen Aerssens, Willem Talloen, 2015, BMC Bioinformatics.

A web application for sample size and power calculation in case-control microbiome studies

Luc Bijnens, Olivier Thas, Karoline Faust, 2016, Bioinform..

Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project.

Bie M. P. Verbist, S. Hochreiter, A. Bender, 2015, Drug discovery today.

Controlling the Reproducibility of AC50 Estimation during Compound Profiling through Bayesian β-Expectation Tolerance Intervals

Bie M. P. Verbist, P. Lebrun, Wilson Tendong, 2020, SLAS discovery : advancing life sciences R & D.

5-Sulfonyl-benzimidazoles as selective CB2 agonists.

Bie M. P. Verbist, J. Aerssens, M. Nijsen, 2008, Bioorganic & medicinal chemistry letters.

Addressing Genotoxicity Risk in Lead Optimization: A PDE10A Inhibitor Case Study

Hinrich W. H. Göhlmann, Bie M. P. Verbist, H. Göhlmann, 2018, Early Drug Development.

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Bie M. P. Verbist, U. Philippar, T. Graubert, 2021, Molecular Cancer Therapeutics.

Design and synthesis of novel type VI-like β-turn mimetics. Diversity at the i+1 and the i+2 position

Bie M. P. Verbist, E. V. D. Eycken, Frederik J. R. Rombouts, 2004 .

Acid catalysed methanolysis of 2,5-diazabicyclo[2.2.2]octane-3,6-diones: scope and limitations

Bie M. P. Verbist, W. D. Borggraeve, F. Compernolle, 2004 .

Development of New Amino(oxo)piperidinecarboxylate Scaffolds and Their Evaluation as -Turn Mimics

Bie M. P. Verbist, S. Toppet, W. D. Borggraeve, 2005 .

Automated quality control tool for high-content imaging data by building 2D prediction intervals on reference biosignatures.

Bie M. P. Verbist, Emmanuel Gustin, A. Assefa, 2023, SLAS discovery : advancing life sciences R & D.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Bie M. P. Verbist, T. Plesner, T. Casneuf, 2016, Blood.

Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants.

Bie M. P. Verbist, J. Aerssens, J. Reumers, 2015, Journal of virological methods.

Stereoselective intramolecular Diels–Alder reactions of 3-alkenyl(oxy)-2(1H)-pyrazinones

Bie M. P. Verbist, E. V. D. Eycken, Frederik J. R. Rombouts, 2002 .

A joint modeling approach for uncovering associations between gene expression, bioactivity and chemical structure in early drug discovery to guide lead selection and genomic biomarker development

Adetayo Kasim, Ziv Shkedy, Willem Talloen, 2016, Statistical applications in genetics and molecular biology.

Integrating High-Dimensional Transcriptomics and Image Analysis Tools into Early Safety Screening: Proof of Concept for a New Early Drug Development Strategy.

Willem Talloen, Bie M. P. Verbist, Freddy Van Goethem, 2015, Chemical research in toxicology.

PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Bie M. P. Verbist, S. Lonial, T. Plesner, 2016 .

Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma

Bie M. P. Verbist, T. Plesner, T. Casneuf, 2015 .

BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism

Olivier Thas, Bie Verbist, Bie M. P. Verbist, 2017, Scientific Reports.

5-sulfonyl-benzimidazoles as selective CB2 agonists-part 2.

Bie M. P. Verbist, T. Meert, J. Aerssens, 2012, Bioorganic & medicinal chemistry letters.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Bie M. P. Verbist, T. Plesner, T. Casneuf, 2016, Blood.

Statistical detection of synergy: New methods and a comparative study

Bie M. P. Verbist, O. Thas, L. Bijnens, 2021, Pharmaceutical statistics.

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

Bie M. P. Verbist, U. Philippar, C. Drenberg, 2022, Blood.

Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project.

Hinrich W. H. Göhlmann, Bie M. P. Verbist, A. Bender, 2015, Drug discovery today.